Organisation paid for research Program year 2025 Source: CMS Open Payments

Arlington Nephrology

Neither a doctor nor a teaching hospital

Research payments

$1,052,030

629 payments

Through program year 2025, Arlington Nephrology is reported as receiving $1,052,030 in research payments, across 629 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,275	1
2024	Research	$12,882	2
2023	Research	$14,796	3
2022	Research	$179,832	10
2021	Research	$101,464	10
2020	Research	$225,920	53
2019	Research	$515,861	550

Breakdown

Who paid Research payments · program years 2019–2025

Akebia Therapeutics Inc $909,219 605 payments
Vertex Pharmaceuticals Incorporated $67,701 7 payments
Sanofi US Services Inc. $45,403 14 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $29,325 1 payment
Pfizer Inc. $381 2 payments

Studies the money was for Research payments · program years 2019–2025

Akb-6548-Ci-0017 $165,694 184 payments
Akb-6548-Ci-0014 $145,788 189 payments
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects $140,703 7 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $105,302 15 payments
Akb-6548-Ci-0016 $93,401 111 payments
Akb-6548-Ci-0017 $62,405 1 payment
Akb-6548-Ci-0015 $59,414 57 payments
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $54,910 4 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction Or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate - Correction/Conversion) $48,592 11 payments
Akb-6548-Ci-0014 $30,286 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.